Search Results

ViroCell Biologics announces a new partnership with University College London to advance Professor Persis Amrolia’s innovative chimeric antigen receptor T-cell therapy for relapsed paediatric acute lymphoblastic leukaemia.

Mercy BioAnalytics, Inc. will present data at the American Society of Clinical Oncology Annual Meeting next month demonstrating the first significant improvement in the early detection of ovarian cancer using a locked assay since CA125 serum biomarker testing and transvaginal ultrasound imaging were introduced nearly 40 years ago.

RespireRx Pharmaceuticals Inc. is pleased to announce the entering into a material transfer agreement with University College London as part of a collaborative research effort involving Dr. Ian Coombs and Prof. Mark Farrant, founder members of the GRIA Scientific Advisory Board of the CureGRIN Foundation and from the UCL Department of Neuroscience, Physiology, and Pharmacology.

In a study published online in CELL , scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings on convergent evolutionary mechanisms shared by COVID-19 variants, allowing them to overcome both adaptive and innate immune system barriers.

Tessellate BIO announces the appointment of Professor Sandra Strauss, University College London, to its Scientific Advisory Board.

Aclarion, Inc. announced their initial payer coverage of Nociscan by AXA in London, UK in conjunction with The London Clinic, one of the UK’s largest and most renowned independent hospitals.

Quoin Pharmaceuticals Ltd., a specialty pharmaceutical company focused on rare and orphan diseases, announced that it has signed a research agreement with The School of Pharmacy at University College Cork, Ireland.

EVONETIX LTD, the Company developing semiconductor scale technology to improve access to gene synthesis, announced its first placement of a DNA synthesis development platform for evaluation at Imperial College London.

Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced plans to open a new office in London’s vibrant King’s Cross neighborhood.

1st May 2024: TechBio company Cytomos (www.cytomos.com) will be giving visitors to this year’s London Biotechnology Show a sneak preview of Celledonia™ – its flagship technology that utilises the company’s patented AuraCyt™ platform.